Viking Therapeutics Jumps 30% on Positive Obesity Drug Data

Viking Therapeutics' stock surged nearly 30% after positive study results for its obesity drug candidate VK2735, positioning it as a potential competitor to Novo Nordisk and Eli Lilly. The data suggests efficacy, but regulatory and commercial viability remain unproven. This development boosts the obesity drug sector and may pressure incumbents' valuations.